Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mike Ross
AddedMar 31, 2024
UpdatedMay 31, 2026
Mike Ross

Mike Ross

Board Member, Deciphera Pharmaceuticals

Crunchbase

Mike Ross's Career

Deciphera Pharmaceuticals
Deciphera Pharmaceuticals

Waltham, MA, US

Board Member· Board
CyThera
CyThera

San Diego, CA, US

Board Member· Board
NKT Therapeutics
NKT Therapeutics

Waltham, MA, US

Board Member· Board
Link Medicine
Link Medicine

Cambridge, MA, US

Board Member· Board
Adimab
Adimab

Lebanon, NH, US

Board Member· Board
Archemix
Archemix

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mike Ross's Career

Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Acquired$1B02003Waltham, MA, US
Board Member· Board

Leadership at Deciphera Pharmaceuticals

Michael D. TaylorMichael D. TaylorCo-Founder
Ron SquarerRon SquarerBoard Member
Patricia AllenPatricia AllenBoard Member
Susan KelleySusan KelleyBoard Member
Daniel L FlynnDaniel L FlynnBoard Member
James A. BristolJames A. BristolBoard Member

Similar to Deciphera Pharmaceuticals

Blueprint MedicinesBlueprint MedicinesCambridge, MA, USCancer Treatmentsest. 2008Blueprint MedicinesCambridge, MA, US · est. 2008

Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.

Public · $2.4B641
Karyopharm TherapeuticsKaryopharm TherapeuticsNewton, MA, USPharmaceuticalsest. 2008Karyopharm TherapeuticsNewton, MA, US · est. 2008

US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.

Public · $546.7M385
BeOne MedicinesBeOne MedicinesCambridge, MA, USCancer Treatmentsest. 2010BeOne MedicinesCambridge, MA, US · est. 2010

BeiGene, a global biopharmaceutical firm, specializes in developing targeted and immuno-oncology cancer treatments.

Public · $6.8B10k
G1 TherapeuticsG1 TherapeuticsTriangle (historical), NC, USCancer Therapiesest. 2008G1 TherapeuticsTriangle (historical), NC, US · est. 2008

US-based G1 Therapeutics develops innovative treatments for oncology and breast cancer.

Public · $697.4M170
CyThera
CyThera

San Diego, CA, US

Board Member· Board
NKT Therapeutics
NKT Therapeutics
Series A$12M82008Waltham, MA, US
Board Member· Board

Leadership at NKT Therapeutics

Mark TepperMark TepperFounder
Robert MashalRobert MashalBoard Member
Dr Samuel Wu \"Sam\"Dr Samuel Wu \"Sam\"Board Member

Similar to NKT Therapeutics

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Nerx BiosciencesNerx BiosciencesIndianapolis, IN, USCancer Therapeuticsest. 2009Nerx BiosciencesIndianapolis, IN, US · est. 2009

US-based NĒRx BioSciences Inc, founded in 2009, specializes in discovering and developing targeted cancer therapeutics.

Seed · $500k11
Nuon TherapeuticsNuon TherapeuticsSan Mateo, CA, USTherapiesest. 2002Nuon TherapeuticsSan Mateo, CA, US · est. 2002

Nuon Therapeutics: A US-based biotech firm innovating therapies for autoimmune and inflammatory diseases.

Series A · $48M75
Link Medicine
Link Medicine
Public$64.8M302005Cambridge, MA, US
Board Member· Board

Leadership at Link Medicine

John DeeJohn DeeBoard Member
Peter LansburyPeter LansburyFounder
Dr Edward M ScolnickDr Edward M ScolnickBoard Member
Adimab
Adimab
Public$45.5M1492007Lebanon, NH, US
Board Member· Board

Leadership at Adimab

Bill MarisBill MarisBoard Member
Tillman GerngrossTillman GerngrossBoard Member
K. Dane WittrupK. Dane WittrupBoard Member
Carl L. GordonCarl L. GordonBoard Member
Terry McguireTerry McguireBoard Member
Philip ChasePhilip ChaseBoard Member
Archemix
Archemix
Public$101.8M752001Cambridge, MA, US
Board Member· Board

Leadership at Archemix

Jean-François FormelaJean-François FormelaFounder
John MaraganoreJohn MaraganoreBoard Member
Bob SteinBob SteinBoard Member

Similar to Archemix

Guardian TherapeuticsGuardian TherapeuticsLexington, MA, USTherapeuticsest. 2017Guardian TherapeuticsLexington, MA, US · est. 2017

Guardian Therapeutics, pioneering the limitless potential of aptamer therapeutics.

Series B · $30M75
Arch TherapeuticsArch TherapeuticsFramingham, MA, USMedical Devicesest. 2009Arch TherapeuticsFramingham, MA, US · est. 2009

Arch Therapeutics: Innovating therapeutic solutions with peptide polymers to control bleeding.

Public · $27M7
KemiaKemiaSan Diego, CA, USPharmaceuticalsest. 2001KemiaSan Diego, CA, US · est. 2001

Discovering therapeutics for inflammation. Serving US healthcare.

Series C · $100M30
OmnioxOmnioxSan Carlos, CA, USBiotechest. 2006OmnioxSan Carlos, CA, US · est. 2006

US-based Omniox, a biotech firm, innovates in cancer, cardiovascular disease, and trauma treatment.

Series D · $20.1M7

Mike Ross's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailHiroshi MikitaniHiroshi MikitaniBoard Member · RakutenKen KutaragiKen KutaragiBoard Member · RakutenTakashi MitachiTakashi MitachiBoard Member · Rakuten

People Similar to Mike Ross

Satish TadikondaSatish TadikondaBoard Member · Blue Cloud VenturesMike LiangMike LiangBoard Member · Illinois VenturesMichael TardugnoMichael TardugnoBoard Member · ImunonScott RocklageScott RocklageBoard Member · WaveRxAlex MendezAlex MendezPartner Emeritus · Storm Ventures